Who are Sin-Bev-TACE's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sin-bev-tace.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Sin-Bev-TACE — Competitive Intelligence Brief

Sin-Bev-TACE (Sin-Bev-TACE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-angiogenic monoclonal antibody combined with chemoembolization. Area: Oncology.

phase 3 Anti-angiogenic monoclonal antibody combined with chemoembolization VEGF (vascular endothelial growth factor) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Sin-Bev-TACE (Sin-Bev-TACE) — Second Affiliated Hospital of Guangzhou Medical University. Sin-Bev-TACE is a combination therapy that pairs bevacizumab (anti-VEGF monoclonal antibody) with transarterial chemoembolization (TACE) to inhibit tumor angiogenesis while delivering chemotherapy directly to hepatic tumors.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sin-Bev-TACE TARGET	Sin-Bev-TACE	Second Affiliated Hospital of Guangzhou Medical University	phase 3	Anti-angiogenic monoclonal antibody combined with chemoembolization	VEGF (vascular endothelial growth factor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-angiogenic monoclonal antibody combined with chemoembolization class)

Second Affiliated Hospital of Guangzhou Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sin-Bev-TACE — Competitive Intelligence Brief. https://druglandscape.com/ci/sin-bev-tace. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab